View Future GrowthHydration Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6Hydration Pharmaceuticals은 연평균 3.9%의 비율로 수입이 증가해 온 반면, Personal Products 산업은 연평균 7.8%의 비율로 증가했습니다. 매출은 연평균 13.2%의 비율로 감소했습니다.핵심 정보3.86%순이익 성장률25.72%주당순이익(EPS) 성장률Personal Products 산업 성장률-25.22%매출 성장률-13.16%자기자본이익률-193.91%순이익률-111.31%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Mar 02Full year 2025 earnings released: US$0.71 loss per share (vs US$0.02 loss in FY 2024)Full year 2025 results: US$0.71 loss per share. Revenue: US$2.47m (down 23% from FY 2024). Net loss: US$2.75m (loss narrowed 52% from FY 2024).Reported Earnings • Aug 31First half 2025 earnings released: US$0.004 loss per share (vs US$0.011 loss in 1H 2024)First half 2025 results: US$0.004 loss per share (improved from US$0.011 loss in 1H 2024). Revenue: US$1.53m (down 69% from 1H 2024). Net loss: US$1.33m (loss narrowed 57% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 05Full year 2024 earnings released: US$0.02 loss per share (vs US$0.037 loss in FY 2023)Full year 2024 results: US$0.02 loss per share (improved from US$0.037 loss in FY 2023). Revenue: US$3.20m (down 26% from FY 2023). Net loss: US$5.67m (loss narrowed 22% from FY 2023).Reported Earnings • Mar 01Full year 2024 earnings released: US$0.021 loss per share (vs US$0.042 loss in FY 2023)Full year 2024 results: US$0.021 loss per share (improved from US$0.042 loss in FY 2023). Revenue: US$3.20m (down 68% from FY 2023). Net loss: US$5.67m (loss narrowed 30% from FY 2023).Reported Earnings • Apr 03Full year 2023 earnings released: US$0.042 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.042 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).모든 업데이트 보기Recent updatesNew Risk • Jun 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (AU$2.64m market cap, or US$1.82m). Minor Risk Revenue is less than US$5m (US$2.5m revenue).공고 • Jun 23The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.392 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.392 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 98,000,000 Price\Range: AUD 0.004 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공고 • Jun 16The Hydration Pharmaceuticals Company Limited Announces Board ChangesThe Hydration Pharmaceuticals Company Limited appointed George Karafotias and Nick Katiforis as Non-Executive Directors, effective June 16, 2026. The Company advised that Adem Karafili and Joseph Constable resigned as Non-Executive Chair and Non-Executive Director respectively, effective on the appointment of Mr. Karafotias and Mr. Katiforis. Nick Berry assumed the role of Non-Executive Chair. George Karafotias is a specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success. His extensive experience includes an established track record with publicly-traded businesses, predominantly in senior executive positions. He holds a Bachelor of Commerce degree from the University of Adelaide. Nick Katiforis is a financial services professional with over 20 years’ experience across capital markets, equities, options and FX. He has been a Director of Futurity Trading, a financial services and trading firm, since 2000 and holds ASIC financial adviser accreditation. He brings extensive experience in client engagement, execution, capital markets distribution and regulatory compliance.공고 • Jun 15The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.392 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.392 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 98,000,000 Price\Range: AUD 0.004 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공고 • Apr 30The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026.Board Change • Mar 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Market cap is less than US$10m (AU$2.15m market cap, or US$1.53m). Minor Risk Revenue is less than US$5m (US$2.5m revenue).Reported Earnings • Mar 02Full year 2025 earnings released: US$0.71 loss per share (vs US$0.02 loss in FY 2024)Full year 2025 results: US$0.71 loss per share. Revenue: US$2.47m (down 23% from FY 2024). Net loss: US$2.75m (loss narrowed 52% from FY 2024).Reported Earnings • Aug 31First half 2025 earnings released: US$0.004 loss per share (vs US$0.011 loss in 1H 2024)First half 2025 results: US$0.004 loss per share (improved from US$0.011 loss in 1H 2024). Revenue: US$1.53m (down 69% from 1H 2024). Net loss: US$1.33m (loss narrowed 57% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.공고 • Jul 10The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,387,853 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,500,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: AUD 0.01 Transaction Features: Rights OfferingNew Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Market cap is less than US$10m (AU$4.68m market cap, or US$3.06m). Minor Risk Revenue is less than US$5m (US$3.2m revenue).Board Change • Apr 12High number of new directorsNon-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025.Reported Earnings • Apr 05Full year 2024 earnings released: US$0.02 loss per share (vs US$0.037 loss in FY 2023)Full year 2024 results: US$0.02 loss per share (improved from US$0.037 loss in FY 2023). Revenue: US$3.20m (down 26% from FY 2023). Net loss: US$5.67m (loss narrowed 22% from FY 2023).New Risk • Apr 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Market cap is less than US$10m (AU$3.70m market cap, or US$2.31m). Minor Risk Revenue is less than US$5m (US$3.2m revenue).공고 • Mar 25The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing공고 • Mar 18+ 1 more updateThe Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,982,614 Price\Range: AUD 0.01 Transaction Features: Rights Offering공고 • Mar 14The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025.Reported Earnings • Mar 01Full year 2024 earnings released: US$0.021 loss per share (vs US$0.042 loss in FY 2023)Full year 2024 results: US$0.021 loss per share (improved from US$0.042 loss in FY 2023). Revenue: US$3.20m (down 68% from FY 2023). Net loss: US$5.67m (loss narrowed 30% from FY 2023).분석 기사 • Jun 25Take Care Before Jumping Onto The Hydration Pharmaceuticals Company Limited (ASX:HPC) Even Though It's 31% CheaperUnfortunately for some shareholders, the The Hydration Pharmaceuticals Company Limited ( ASX:HPC ) share price has...Board Change • May 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • May 24The Hydration Pharmaceuticals Company Limited Announces Board Change, Effective 25 May 2024The Hydration Pharmaceuticals Company Limited announced that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr. Nick Berry will be appointed as a non-executive Director, effective 25 May 2024. Mr. Nick Berry's appointment as non-executive director will be effective following the resignation of Mr. George Livery on 25 May 2024. Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd. Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors.분석 기사 • May 02Sentiment Still Eluding The Hydration Pharmaceuticals Company Limited (ASX:HPC)The Hydration Pharmaceuticals Company Limited's ( ASX:HPC ) price-to-sales (or "P/S") ratio of 0.3x might make it look...Reported Earnings • Apr 03Full year 2023 earnings released: US$0.042 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.042 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).공고 • Feb 22The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024.New Risk • Oct 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (AU$9.53m market cap, or US$6.06m).New Risk • Sep 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Market cap is less than US$10m (AU$9.97m market cap, or US$6.40m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).Reported Earnings • Sep 04First half 2023 earnings released: US$0.022 loss per share (vs US$0.026 loss in 1H 2022)First half 2023 results: US$0.022 loss per share (improved from US$0.026 loss in 1H 2022). Revenue: US$5.30m (up 28% from 1H 2022). Net loss: US$3.53m (loss narrowed 17% from 1H 2022).공고 • Aug 29The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023The Hydration Pharmaceuticals Company Limited announced that Ms. Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26th of September.New Risk • Aug 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (AU$7.12m market cap, or US$4.62m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding).공고 • Aug 12The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 33,333,337 Price\Range: AUD 0.045 Discount Per Security: AUD 0.0027 Security Features: Attached Options Transaction Features: Subsequent Direct ListingReported Earnings • Mar 01Full year 2022 earnings released: US$0.07 loss per share (vs US$0.12 loss in FY 2021)Full year 2022 results: US$0.07 loss per share. Revenue: US$9.10m (up 49% from FY 2021). Net loss: US$10.6m (loss widened 19% from FY 2021).공고 • Feb 08The Hydration Pharmaceuticals Company Limited Announces Executive ChangesThe Hydration Pharmaceuticals Company Limited announced the appointment of Victoria Nadalin as Company Secretary upon the resignation of Carlie Hodges, effective 8 February 2023. Victoria is a practising corporate and commercial lawyer and is completing a Graduate Diploma in Applied Corporate Governance and Risk Management with the Governance Institute of Australia.공고 • Dec 03The Hydration Pharmaceuticals Company Limited Launches Co-Branded ProductThe Hydration Pharmaceuticals Company Limited advised it has successfully launched its co-branded stockkeeping unit (SKU) alongside brand ambassador and entrepreneur, Ms. Shay Mitchell. The new product is being sold through Hydralyte North America's ecommerce channels, as well as Amazon USA. RiteAid, a major US retailer, will stock the product in the coming weeks, while additional ranging across additional retail outlets will occur in the coming weeks. The initial launch through online channels provides Hydralyte North America with the opportunity to leverage its established customer base, which has grown considerably in the past 12 months. Amazon US sales rose 62% on the prior corresponding period during Third Quarter FY2022, with customer subscriptions increasing 5% to 12% per month during FY2022. Ms. Mitchell's co-branded SKU has been launched in two sizes; a six-stick box designed for traditional retail outlets, as well as a larger 18 stick value pack for more convenient and higher margin sales across ecommerce channels (refer images overleaf). The launch follows an extensive period of production development in direct collaboration with Ms. Mitchell, which involved flavour testing, packaging design, manufacturing, and consultation on online and in-person marketing strategies. The launch will be complemented by a two-day marketing event, hosted by Ms Mitchell in Florida. The marketing installation is positioned to bring together 16 of America's top influencers, each of which have large individual social media follower bases and has the potential to deliver considerable value from social media posts and brand awareness. The one-off costs associated with the event have already been realised by the Company. It is expected that Ms. Mitchell will also be able to leverage her established social media presence to boost awareness of the new product launch. As a gauge of Ms. Mitchell's popularity in the Company's core target markets, her social media presence currently stands at 34.9m Instagram followers, 2.9m Twitter followers, 4.18m YouTube subscribers and 7.3m followers on TikTok.공고 • Dec 02Shay Mitchell Debuts New Lemon Squeeze Flavor Rapid Hydration Drink in Collaboration with HydraLyteHydraLyte announced that Shay Mitchell, actress, producer and entrepreneur, announced her collaboration with HydraLyte to launch her new flavor, Lemon Squeeze. Since the announcement of their partnership in May of 2022, Mitchell has led the co-development process to create a rejuvenating hydration option for the entire family. Throughout the process, Mitchell assumed an elevated role as an investor and part owner in the company, personally testing 12 variations of the product to find the perfect flavor balance. Beyond just perfecting a delicious flavor, Mitchell remained closely involved in the journey, spearheading execution details such as packaging, marketing strategy, and creative. This citrusy electrolyte mix is sized to serve in 16-ounces of water and is proven to be effective in preventing and relieving mild to moderate dehydration. Trusted by the medical community, professional athletes and families around the world, HydraLyte's products are acclaimed for their all-natural formula scientifically developed with: Almost half the sugar of leading electrolyte drink brands; Clean, vegan, non-GMO ingredients; No artificial colors, flavors or sweeteners, gluten, dairy, or caffeine; and A ratio of glucose and electrolytes that activates rapid rehydration faster than water alone. HydraLyte x Shay Mitchell Lemon Squeeze flavor will be available for $24.99 on the HydraLyte website and Amazon on November 30, 2022 with more retailers to come in the new year.공고 • Nov 16Hydration Pharmaceuticals Company Limited Secures Key Regulatory Approval for Product Manufacturing for the Canadian MarketThe Hydration Pharmaceuticals Company Limited confirm it has secured key regulatory approval for product manufacturing for the Canadian market. The Company advises that it has formally received manufacturing approval from Health Canada - a key regulatory update which allows Hydralyte North America's US-based contract manufacturer to commence production of the Company's liquid range for the Canadian market. The Health Canada approval was viewed by the management team as a strategic priority which allows the Company to optimise its manufacturing processes from a centralised production hub, and capitalise on its existing distribution channels across the North American market. Hydralyte North America currently sells four stock keeping units (SKU) under its ready-to-drink range which are stocked by major Canadian retail outlets, including Shoppers Drug Mart and a large number of independent stores. Securing Health Canada approval for manufacturing in the US is expected to lead to a reduction in cost of goods sold, cheaper freights and potentially underpin an increase in gross margins for the Company's liquid SKUs.Reported Earnings • Aug 31First half 2022 earnings released: US$0.03 loss per share (vs US$0.039 loss in 1H 2021)First half 2022 results: US$0.03 loss per share. Revenue: US$4.13m (up 80% from 1H 2021). Net loss: US$4.24m (loss widened 92% from 1H 2021).Reported Earnings • Apr 06Full year 2021 earnings released: US$0.12 loss per share (vs US$0.011 loss in FY 2020)Full year 2021 results: US$0.12 loss per share (down from US$0.011 loss in FY 2020). Revenue: US$6.13m (up 63% from FY 2020). Net loss: US$8.95m (loss widened US$8.21m from FY 2020).공고 • Mar 31The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 27, 2022The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 27, 2022.분석 기사 • Mar 15Is Hydration Pharmaceuticals (ASX:HPC) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Mar 01Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$5.92m (up 57% from FY 2020). Net loss: US$8.97m (loss widened US$8.22m from FY 2020). Revenue was in line with analyst estimates.공고 • Feb 08The Hydration Pharmaceuticals Company Limited Announces Management AppointmentsThe Hydration Pharmaceuticals Company Limited announced it has appointed experienced US business executive Margaret Hardin to its Board as an Independent Non-Executive Director. Ms. Hardin is a global products senior executive and board director, who has previously scaled two consumer goods companies to generate more than USD100 million in revenue, and currently advises founders on growth opportunities. As CEO of ERGObaby Carrier Inc. from 2013 to 2020, Ms Hardin revived product innovation while managing an omni-channel distributor, retail and eCommerce model across more than 60 countries and 19 company-owned websites. In addition, Vanessa Dew, an entrepreneur and investor from Los Angeles, has joined Hydralyte North America's advisory team. Ms. Dew is the co-founder and Chief Sales Officer of Health-Ade, one of the largest kombucha brands in the USA. Concurrently, she has worked with several emerging, innovative brands as a board member and advisor.Board Change • Dec 31High number of new directorsIndependent Non-Executive Chairman George Livery was the last director to join the board, commencing their role in 2021.공고 • Dec 11The Hydration Pharmaceuticals Company Limited has completed an IPO in the amount of AUD 17 million.The Hydration Pharmaceuticals Company Limited has completed an IPO in the amount of AUD 17 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 58,620,690 Price\Range: AUD 0.29 Discount Per Security: AUD 0.01595매출 및 비용 세부 내역Hydration Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ASX:HPC 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 252-35030 Sep 253-45030 Jun 253-55031 Mar 253-55031 Dec 243-66030 Jun 241-65031 Mar 243-77031 Dec 234-79030 Sep 2310-914030 Jun 2310-1015031 Mar 2310-1015031 Dec 229-1115030 Sep 229-1114030 Jun 228-1114031 Mar 227-1012031 Dec 216-910030 Sep 215-67030 Jun 214-45031 Mar 214-25031 Dec 204-15031 Dec 193-35031 Dec 184-1090양질의 수익: HPC 은(는) 현재 수익성이 없습니다.이익 마진 증가: HPC는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: HPC는 수익성이 없지만 지난 5년 동안 연평균 3.9%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 HPC의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: HPC은 수익성이 없어 지난 해 수익 성장률을 Personal Products 업계(6.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: HPC는 현재 수익성이 없으므로 자본 수익률이 음수(-193.91%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHousehold 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/17 14:56종가2026/07/16 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스The Hydration Pharmaceuticals Company Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Mar 02Full year 2025 earnings released: US$0.71 loss per share (vs US$0.02 loss in FY 2024)Full year 2025 results: US$0.71 loss per share. Revenue: US$2.47m (down 23% from FY 2024). Net loss: US$2.75m (loss narrowed 52% from FY 2024).
Reported Earnings • Aug 31First half 2025 earnings released: US$0.004 loss per share (vs US$0.011 loss in 1H 2024)First half 2025 results: US$0.004 loss per share (improved from US$0.011 loss in 1H 2024). Revenue: US$1.53m (down 69% from 1H 2024). Net loss: US$1.33m (loss narrowed 57% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 05Full year 2024 earnings released: US$0.02 loss per share (vs US$0.037 loss in FY 2023)Full year 2024 results: US$0.02 loss per share (improved from US$0.037 loss in FY 2023). Revenue: US$3.20m (down 26% from FY 2023). Net loss: US$5.67m (loss narrowed 22% from FY 2023).
Reported Earnings • Mar 01Full year 2024 earnings released: US$0.021 loss per share (vs US$0.042 loss in FY 2023)Full year 2024 results: US$0.021 loss per share (improved from US$0.042 loss in FY 2023). Revenue: US$3.20m (down 68% from FY 2023). Net loss: US$5.67m (loss narrowed 30% from FY 2023).
Reported Earnings • Apr 03Full year 2023 earnings released: US$0.042 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.042 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).
Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).
New Risk • Jun 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (AU$2.64m market cap, or US$1.82m). Minor Risk Revenue is less than US$5m (US$2.5m revenue).
공고 • Jun 23The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.392 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.392 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 98,000,000 Price\Range: AUD 0.004 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공고 • Jun 16The Hydration Pharmaceuticals Company Limited Announces Board ChangesThe Hydration Pharmaceuticals Company Limited appointed George Karafotias and Nick Katiforis as Non-Executive Directors, effective June 16, 2026. The Company advised that Adem Karafili and Joseph Constable resigned as Non-Executive Chair and Non-Executive Director respectively, effective on the appointment of Mr. Karafotias and Mr. Katiforis. Nick Berry assumed the role of Non-Executive Chair. George Karafotias is a specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success. His extensive experience includes an established track record with publicly-traded businesses, predominantly in senior executive positions. He holds a Bachelor of Commerce degree from the University of Adelaide. Nick Katiforis is a financial services professional with over 20 years’ experience across capital markets, equities, options and FX. He has been a Director of Futurity Trading, a financial services and trading firm, since 2000 and holds ASIC financial adviser accreditation. He brings extensive experience in client engagement, execution, capital markets distribution and regulatory compliance.
공고 • Jun 15The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.392 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.392 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 98,000,000 Price\Range: AUD 0.004 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공고 • Apr 30The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026.
Board Change • Mar 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Market cap is less than US$10m (AU$2.15m market cap, or US$1.53m). Minor Risk Revenue is less than US$5m (US$2.5m revenue).
Reported Earnings • Mar 02Full year 2025 earnings released: US$0.71 loss per share (vs US$0.02 loss in FY 2024)Full year 2025 results: US$0.71 loss per share. Revenue: US$2.47m (down 23% from FY 2024). Net loss: US$2.75m (loss narrowed 52% from FY 2024).
Reported Earnings • Aug 31First half 2025 earnings released: US$0.004 loss per share (vs US$0.011 loss in 1H 2024)First half 2025 results: US$0.004 loss per share (improved from US$0.011 loss in 1H 2024). Revenue: US$1.53m (down 69% from 1H 2024). Net loss: US$1.33m (loss narrowed 57% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
공고 • Jul 10The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,387,853 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,500,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: AUD 0.01 Transaction Features: Rights Offering
New Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Market cap is less than US$10m (AU$4.68m market cap, or US$3.06m). Minor Risk Revenue is less than US$5m (US$3.2m revenue).
Board Change • Apr 12High number of new directorsNon-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025.
Reported Earnings • Apr 05Full year 2024 earnings released: US$0.02 loss per share (vs US$0.037 loss in FY 2023)Full year 2024 results: US$0.02 loss per share (improved from US$0.037 loss in FY 2023). Revenue: US$3.20m (down 26% from FY 2023). Net loss: US$5.67m (loss narrowed 22% from FY 2023).
New Risk • Apr 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Market cap is less than US$10m (AU$3.70m market cap, or US$2.31m). Minor Risk Revenue is less than US$5m (US$3.2m revenue).
공고 • Mar 25The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
공고 • Mar 18+ 1 more updateThe Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,982,614 Price\Range: AUD 0.01 Transaction Features: Rights Offering
공고 • Mar 14The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025.
Reported Earnings • Mar 01Full year 2024 earnings released: US$0.021 loss per share (vs US$0.042 loss in FY 2023)Full year 2024 results: US$0.021 loss per share (improved from US$0.042 loss in FY 2023). Revenue: US$3.20m (down 68% from FY 2023). Net loss: US$5.67m (loss narrowed 30% from FY 2023).
분석 기사 • Jun 25Take Care Before Jumping Onto The Hydration Pharmaceuticals Company Limited (ASX:HPC) Even Though It's 31% CheaperUnfortunately for some shareholders, the The Hydration Pharmaceuticals Company Limited ( ASX:HPC ) share price has...
Board Change • May 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • May 24The Hydration Pharmaceuticals Company Limited Announces Board Change, Effective 25 May 2024The Hydration Pharmaceuticals Company Limited announced that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr. Nick Berry will be appointed as a non-executive Director, effective 25 May 2024. Mr. Nick Berry's appointment as non-executive director will be effective following the resignation of Mr. George Livery on 25 May 2024. Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd. Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors.
분석 기사 • May 02Sentiment Still Eluding The Hydration Pharmaceuticals Company Limited (ASX:HPC)The Hydration Pharmaceuticals Company Limited's ( ASX:HPC ) price-to-sales (or "P/S") ratio of 0.3x might make it look...
Reported Earnings • Apr 03Full year 2023 earnings released: US$0.042 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.042 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).
Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).
공고 • Feb 22The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024.
New Risk • Oct 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (AU$9.53m market cap, or US$6.06m).
New Risk • Sep 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Market cap is less than US$10m (AU$9.97m market cap, or US$6.40m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).
Reported Earnings • Sep 04First half 2023 earnings released: US$0.022 loss per share (vs US$0.026 loss in 1H 2022)First half 2023 results: US$0.022 loss per share (improved from US$0.026 loss in 1H 2022). Revenue: US$5.30m (up 28% from 1H 2022). Net loss: US$3.53m (loss narrowed 17% from 1H 2022).
공고 • Aug 29The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023The Hydration Pharmaceuticals Company Limited announced that Ms. Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26th of September.
New Risk • Aug 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (AU$7.12m market cap, or US$4.62m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding).
공고 • Aug 12The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 33,333,337 Price\Range: AUD 0.045 Discount Per Security: AUD 0.0027 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Reported Earnings • Mar 01Full year 2022 earnings released: US$0.07 loss per share (vs US$0.12 loss in FY 2021)Full year 2022 results: US$0.07 loss per share. Revenue: US$9.10m (up 49% from FY 2021). Net loss: US$10.6m (loss widened 19% from FY 2021).
공고 • Feb 08The Hydration Pharmaceuticals Company Limited Announces Executive ChangesThe Hydration Pharmaceuticals Company Limited announced the appointment of Victoria Nadalin as Company Secretary upon the resignation of Carlie Hodges, effective 8 February 2023. Victoria is a practising corporate and commercial lawyer and is completing a Graduate Diploma in Applied Corporate Governance and Risk Management with the Governance Institute of Australia.
공고 • Dec 03The Hydration Pharmaceuticals Company Limited Launches Co-Branded ProductThe Hydration Pharmaceuticals Company Limited advised it has successfully launched its co-branded stockkeeping unit (SKU) alongside brand ambassador and entrepreneur, Ms. Shay Mitchell. The new product is being sold through Hydralyte North America's ecommerce channels, as well as Amazon USA. RiteAid, a major US retailer, will stock the product in the coming weeks, while additional ranging across additional retail outlets will occur in the coming weeks. The initial launch through online channels provides Hydralyte North America with the opportunity to leverage its established customer base, which has grown considerably in the past 12 months. Amazon US sales rose 62% on the prior corresponding period during Third Quarter FY2022, with customer subscriptions increasing 5% to 12% per month during FY2022. Ms. Mitchell's co-branded SKU has been launched in two sizes; a six-stick box designed for traditional retail outlets, as well as a larger 18 stick value pack for more convenient and higher margin sales across ecommerce channels (refer images overleaf). The launch follows an extensive period of production development in direct collaboration with Ms. Mitchell, which involved flavour testing, packaging design, manufacturing, and consultation on online and in-person marketing strategies. The launch will be complemented by a two-day marketing event, hosted by Ms Mitchell in Florida. The marketing installation is positioned to bring together 16 of America's top influencers, each of which have large individual social media follower bases and has the potential to deliver considerable value from social media posts and brand awareness. The one-off costs associated with the event have already been realised by the Company. It is expected that Ms. Mitchell will also be able to leverage her established social media presence to boost awareness of the new product launch. As a gauge of Ms. Mitchell's popularity in the Company's core target markets, her social media presence currently stands at 34.9m Instagram followers, 2.9m Twitter followers, 4.18m YouTube subscribers and 7.3m followers on TikTok.
공고 • Dec 02Shay Mitchell Debuts New Lemon Squeeze Flavor Rapid Hydration Drink in Collaboration with HydraLyteHydraLyte announced that Shay Mitchell, actress, producer and entrepreneur, announced her collaboration with HydraLyte to launch her new flavor, Lemon Squeeze. Since the announcement of their partnership in May of 2022, Mitchell has led the co-development process to create a rejuvenating hydration option for the entire family. Throughout the process, Mitchell assumed an elevated role as an investor and part owner in the company, personally testing 12 variations of the product to find the perfect flavor balance. Beyond just perfecting a delicious flavor, Mitchell remained closely involved in the journey, spearheading execution details such as packaging, marketing strategy, and creative. This citrusy electrolyte mix is sized to serve in 16-ounces of water and is proven to be effective in preventing and relieving mild to moderate dehydration. Trusted by the medical community, professional athletes and families around the world, HydraLyte's products are acclaimed for their all-natural formula scientifically developed with: Almost half the sugar of leading electrolyte drink brands; Clean, vegan, non-GMO ingredients; No artificial colors, flavors or sweeteners, gluten, dairy, or caffeine; and A ratio of glucose and electrolytes that activates rapid rehydration faster than water alone. HydraLyte x Shay Mitchell Lemon Squeeze flavor will be available for $24.99 on the HydraLyte website and Amazon on November 30, 2022 with more retailers to come in the new year.
공고 • Nov 16Hydration Pharmaceuticals Company Limited Secures Key Regulatory Approval for Product Manufacturing for the Canadian MarketThe Hydration Pharmaceuticals Company Limited confirm it has secured key regulatory approval for product manufacturing for the Canadian market. The Company advises that it has formally received manufacturing approval from Health Canada - a key regulatory update which allows Hydralyte North America's US-based contract manufacturer to commence production of the Company's liquid range for the Canadian market. The Health Canada approval was viewed by the management team as a strategic priority which allows the Company to optimise its manufacturing processes from a centralised production hub, and capitalise on its existing distribution channels across the North American market. Hydralyte North America currently sells four stock keeping units (SKU) under its ready-to-drink range which are stocked by major Canadian retail outlets, including Shoppers Drug Mart and a large number of independent stores. Securing Health Canada approval for manufacturing in the US is expected to lead to a reduction in cost of goods sold, cheaper freights and potentially underpin an increase in gross margins for the Company's liquid SKUs.
Reported Earnings • Aug 31First half 2022 earnings released: US$0.03 loss per share (vs US$0.039 loss in 1H 2021)First half 2022 results: US$0.03 loss per share. Revenue: US$4.13m (up 80% from 1H 2021). Net loss: US$4.24m (loss widened 92% from 1H 2021).
Reported Earnings • Apr 06Full year 2021 earnings released: US$0.12 loss per share (vs US$0.011 loss in FY 2020)Full year 2021 results: US$0.12 loss per share (down from US$0.011 loss in FY 2020). Revenue: US$6.13m (up 63% from FY 2020). Net loss: US$8.95m (loss widened US$8.21m from FY 2020).
공고 • Mar 31The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 27, 2022The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 27, 2022.
분석 기사 • Mar 15Is Hydration Pharmaceuticals (ASX:HPC) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Mar 01Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$5.92m (up 57% from FY 2020). Net loss: US$8.97m (loss widened US$8.22m from FY 2020). Revenue was in line with analyst estimates.
공고 • Feb 08The Hydration Pharmaceuticals Company Limited Announces Management AppointmentsThe Hydration Pharmaceuticals Company Limited announced it has appointed experienced US business executive Margaret Hardin to its Board as an Independent Non-Executive Director. Ms. Hardin is a global products senior executive and board director, who has previously scaled two consumer goods companies to generate more than USD100 million in revenue, and currently advises founders on growth opportunities. As CEO of ERGObaby Carrier Inc. from 2013 to 2020, Ms Hardin revived product innovation while managing an omni-channel distributor, retail and eCommerce model across more than 60 countries and 19 company-owned websites. In addition, Vanessa Dew, an entrepreneur and investor from Los Angeles, has joined Hydralyte North America's advisory team. Ms. Dew is the co-founder and Chief Sales Officer of Health-Ade, one of the largest kombucha brands in the USA. Concurrently, she has worked with several emerging, innovative brands as a board member and advisor.
Board Change • Dec 31High number of new directorsIndependent Non-Executive Chairman George Livery was the last director to join the board, commencing their role in 2021.
공고 • Dec 11The Hydration Pharmaceuticals Company Limited has completed an IPO in the amount of AUD 17 million.The Hydration Pharmaceuticals Company Limited has completed an IPO in the amount of AUD 17 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 58,620,690 Price\Range: AUD 0.29 Discount Per Security: AUD 0.01595